HCM
RGLS

Highbridge Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Highbridge Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-101
Closed -$205K – 1621
2015
Q1 		$205K Buy
+101
New +$219K ﹤0.01% 1269

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Highbridge Capital Management's RGLS Position: Q4 2016 in Review

Highbridge Capital Management sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 868 shares — an estimated $343K sold.

Highbridge Capital Management first reported a position in RGLS in Q4 2015 and held it in 2 quarters. The position peaked at $343K in Q3 2016. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

  • Highbridge Capital Management reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 868 Regulus Therapeutics shares in Q4 2016, an estimated $343K.
  • Highbridge Capital Management first reported a position in Regulus Therapeutics in Q4 2015 and held it in 2 quarters.
  • Highbridge Capital Management's Regulus Therapeutics position peaked at $343K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.